AnalysisNews

VTVT today

$20.69-$0.78 (-3.63%)close Nov 12, 2026

Trend

DailyDowntrend (confirmed)

4 hourStrong Bearish

1 hourLeaning Bearish

15 minLeaning Bullish

5 minConsolidating

Daily trend turns up above $27.01

Key levels

Resistance$25.00

Resistance$22.91

Support$20.56

Support$18.99

Latest news & SEC filings

EarningsNov 6, 2026vTv Therapeutics Posts Q3 2026 Results, Gives Business Update

EarningsNov 5, 2026vTv Therapeutics reports Q3 EPS of $(0.94), beating $(1.09) estimate

SEC FilingNov 5, 2026vTv Therapeutics Inc. filed a report on a major company event (Form 8-K)

EarningsNov 5, 2026vTv Therapeutics to report Q3 2026 financial results

All VTVT news →

About vTv Therapeutics

vTv Therapeutics is a biopharmaceutical company that creates medicines taken by mouth to treat metabolic and inflammatory conditions. Its main candidate, cadisegliatin, is a liver-selective glucokinase activator in late-stage testing as an add-on to insulin for type 1 diabetes, plus a mid-stage type 2 diabetes study conducted with a partner in the Middle East. Other pipeline assets include an oral small-molecule GLP-1 receptor agonist and a PDE4 inhibitor, advanced through collaborations with pharmaceutical and academic partners.

Based on the company's 10-K filed Mar 10, 2026.

Nasdaq · Healthcare

vTv Therapeutics Inc. (VTVT)

$21.30-0.17 (-0.79%)
WATCHLISTGrade: BRisk: MEDIUM
1D5D1M1Y5YMaxSign up for all timeframes
23.0425.0727.1129.1421.30Oct 12Oct 20Oct 28Nov 5
High21.30
Low21.30
Open21.30
Volume230
Avg Vol16K
VWAP21.30
30d High31.18
30d Low21.00
30d Chg-30.32%
See full chart with real-time data

What Is the Price Target for VTVT?

SEPT Low Target

$57.00

SEPT Mid Target

$57.00

SEPT High Target

$57.00

Analyst Consensus

$57.00

Current: $21.47Upside: +165.5%Confidence: 40%Method: Analyst Consensus

Is VTVT a Buy or Sell Right Now?

56
Investability Score
WATCHLIST12-18 months
News summary · last 30 days
Oct 27▲ UpProduct2 articles
vTv Therapeutics announced it has randomized the first participant in a Phase 2a pilot study of its drug candidate Cadisegliatin, aimed at treating type 1 diabetes, with dosing now underway in the Hybrid CATT1 trial. Despite this bullish clinical milestone, the stock closed at $25.64, down 1.61% from the open of $26.06, trading in a range between $25.47 and $26.51 on light volume of 10,347 shares. The positive trial news did not translate into a same-day price gain, suggesting the early-stage nature of the study may have limited immediate investor reaction. The direction signal from the news is UP, given the medium-impact bullish sentiment around the product catalyst.

Thesis

  • •Revenue growing -49.6% YoY with DECLINING trend — consistent growth.

AI-Powered Trading Signals

Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for VTVT.

Start Free Trial →

Is VTVT Overvalued or Undervalued?

Valuation Verdict

UNDERVALUED

Methods Used

Analyst Consensus

Fair Value

$57.00

10

Moat Score

NONE

4/9

Piotroski Score

N/A

Altman Z-Score

What Is Smart Money Doing with VTVT?

Insider Signal

NEUTRAL

0 buys / 0 sells (90d)

Congress Signal

NEUTRAL

0 buys / 0 sells (90d)

Institutional

N/A

Short Squeeze Risk

HIGH

Signal: HIGH_SHORT_INTEREST

Track Smart Money Across 4,000+ Stocks

Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.

See All Smart Money Signals →

VTVT Growth Story

Revenue YoY

-49.6%

3yr Revenue CAGR

N/A%

EPS Growth YoY

N/A

FCF Growth YoY

N/A%

Revenue Trend

DECLINING

Dark Pool Trades for VTVT

PREVIEW

SEPT Investing tracks real-time dark pool institutional trades for VTVT, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.

TimePriceSizeValueSide
17:44:49$20.882,000$$42KSELL
21:01:57$23.551,007$$24KBUY
20:42:22$24.332,303$$56KBUY
13:46:53$27.471,000$$27KSELL
19:42:11$26.252,542$$67KSELL

5 dark pool trades shown · $$216K preview volume

Real-time institutional flow, block trades, and net positioning

See all dark pool activity

Full AI Research Report

SEPT's Trading AI has generated a free, downloadable PDF research report for vTv Therapeutics Inc. (VTVT) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.

Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...

Sign Up Free — Download AI Report PDF →

AI-Powered Trading Signals.

Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.

Try SEPT Free for 7 Days →

Compare SEPT with other platforms

SEPT vs TradingViewSEPT vs BloombergSEPT vs Unusual WhalesSEPT vs SpotGammaSEPT vs TrendSpiderAI Trading Platforms Compared
What is dark pool trading?How to read options flowGEX explainedSmart money trackingAI stock analysisEarn money on SEPT

About SEPT Investing

SEPT Investing tracks 13,000+ stocks with live charts, trend and key-level tracking, dark pool and options flow, insider and congress trades, SEC filings and news alerts.

Disclaimer: This page is for informational purposes only. It does not constitute financial advice. Past performance does not guarantee future results. Always do your own research before making investment decisions.

VTVT — frequently asked questions

What is VTVT stock price today?

vTv Therapeutics Inc. (VTVT) is at $20.69, down 3.63% (-$0.78) at the Nov 12, 2026 close.

Why is VTVT stock moving today?

Latest VTVT news — Nov 6, 2026: vTv Therapeutics Posts Q3 2026 Results, Gives Business Update · Nov 5, 2026: vTv Therapeutics reports Q3 EPS of $(0.94), beating $(1.09) estimate

Why did VTVT stock move on Oct 27, 2026?

vTv Therapeutics announced it has randomized the first participant in a Phase 2a pilot study of its drug candidate Cadisegliatin, aimed at treating type 1 diabetes, with dosing now underway in the Hybrid CATT1 trial. Despite this bullish clinical milestone, the stock closed at $25.64, down 1.61% from the open of $26.06, trading in a range between $25.47 and $26.51 on light volume of 10,347 shares.

What is the VTVT price target?

The average analyst price target for VTVT is $57.00, ranging from $57 to $57, based on 2 analysts.

What do analysts rate VTVT?

Analyst ratings for VTVT: 0 Buy, 2 Hold, 0 Sell — consensus Hold.

Did VTVT beat earnings?

VTVT last reported on Nov 5, 2026: EPS -$0.94 vs -$1.09 expected — a beat of 13.8%.

Does VTVT pay a dividend?

VTVT does not currently pay a dividend.

What are VTVT support and resistance levels?

Support: $20.56, $18.99, $17.03. Resistance: $22.91, $25.00, $27.01.

What are insiders doing with VTVT?

Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.

What is the latest news on VTVT?

Nov 6, 2026: vTv Therapeutics Posts Q3 2026 Results, Gives Business Update · Nov 5, 2026: vTv Therapeutics reports Q3 EPS of $(0.94), beating $(1.09) estimate · Nov 5, 2026: vTv Therapeutics Inc. filed a report on a major company event (Form 8-K)